Literature DB >> 25210884

Graves' hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease.

Basil Rapoport1, Sandra M McLachlan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25210884      PMCID： PMC4223433          DOI： 10.1210/jc.2014-3011

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  9 in total

Review 1.  Why measure thyroglobulin autoantibodies rather than thyroid peroxidase autoantibodies?

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Thyroid       Date:  2004-07       Impact factor: 6.568

2.  Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response.

Authors:  R C Aalberse; R van der Gaag; J van Leeuwen
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

3.  Thyroid-stimulating antibody activity between different immunoglobulin G subclasses.

Authors:  A P Weetman; M E Yateman; P A Ealey; C M Black; C B Reimer; R C Williams; B Shine; N J Marshall
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

4.  Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample.

Authors:  Michele Evans; Jane Sanders; Tetsuya Tagami; Paul Sanders; Stuart Young; Emma Roberts; Jane Wilmot; Xiaoling Hu; Katarzyna Kabelis; Jill Clark; Sabrina Holl; Tonya Richards; Alastair Collyer; Jadwiga Furmaniak; Bernard Rees Smith
Journal:  Clin Endocrinol (Oxf)       Date:  2010-06-09       Impact factor: 3.478

Review 5.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

Review 6.  Thyroid peroxidase as an autoantigen.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Thyroid       Date:  2007-10       Impact factor: 6.568

Review 7.  Graves' animal models of Graves' hyperthyroidism.

Authors:  Yuji Nagayama
Journal:  Thyroid       Date:  2007-10       Impact factor: 6.568

8.  Affinity-enrichment of thyrotropin receptor autoantibodies from Graves' patients and normal individuals provides insight into their properties and possible origin from natural antibodies.

Authors:  Francesco Latrofa; Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

9.  The expression of dual oxidase, thyroid peroxidase, and caveolin-1 differs according to the type of immune response (TH1/TH2) involved in thyroid autoimmune disorders.

Authors:  Lancelot Marique; Victoria Van Regemorter; Anne-Catherine Gérard; Julie Craps; Maximin Senou; Etienne Marbaix; Jacques Rahier; Chantal Daumerie; Michel Mourad; Benoît Lengelé; Ides M Colin; Marie-Christine Many
Journal:  J Clin Endocrinol Metab       Date:  2014-01-29       Impact factor: 5.958
  9 in total
  26 in total

Review 1.  The thyroid, the eyes and the gut: a possible connection.

Authors:  D Covelli; M Ludgate
Journal:  J Endocrinol Invest       Date:  2017-01-07       Impact factor: 4.256

2.  Decreased expression of microRNA-125a-3p upregulates interleukin-23 receptor in patients with Hashimoto's thyroiditis.

Authors:  Huiyong Peng; Yingzhao Liu; Jie Tian; Jie Ma; Xinyi Tang; Jun Yang; Ke Rui; Yue Zhang; Chaoming Mao; Liwei Lu; Huaxi Xu; Shengjun Wang
Journal:  Immunol Res       Date:  2015-06       Impact factor: 2.829

3.  Overexpression of Interleukin-4 in the Thyroid of Transgenic Mice Upregulates the Expression of Duox1 and the Anion Transporter Pendrin.

Authors:  Zineb Eskalli; Younes Achouri; Stephan Hahn; Marie-Christine Many; Julie Craps; Samuel Refetoff; Xiao-Hui Liao; Jacques E Dumont; Jacqueline Van Sande; Bernard Corvilain; Françoise Miot; Xavier De Deken
Journal:  Thyroid       Date:  2016-10       Impact factor: 6.568

4.  Iodine-131 therapy alters the immune/inflammatory responses in the thyroids of patients with Graves' disease.

Authors:  Wenhua Du; Qingyu Dong; Xiaoting Lu; Xiaomeng Liu; Yueli Wang; Wenxia Li; Zhenyu Pan; Qian Gong; Cuige Liang; Guanqi Gao
Journal:  Exp Ther Med       Date:  2017-01-16       Impact factor: 2.447

5.  Recurrence of Graves' Disease (a Th1-type Cytokine Disease) Following SARS-CoV-2 mRNA Vaccine Administration: A Simple Coincidence?

Authors:  Guillaume Pierman; Etienne Delgrange; Corinne Jonas
Journal:  Eur J Case Rep Intern Med       Date:  2021-09-02

Review 6.  2021 update on thyroid-associated ophthalmopathy.

Authors:  E J Neag; T J Smith
Journal:  J Endocrinol Invest       Date:  2021-08-20       Impact factor: 5.467

Review 7.  A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves' disease.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocrine       Date:  2019-09-27       Impact factor: 3.633

8.  Identification of novel HLA-A0201-restricted T-cell epitopes against thyroid antigens in autoimmune thyroid diseases.

Authors:  Yun Cai; Xinyu Xu; Zheng Zhang; Ping Wang; Qingfang Hu; Yu Jin; Zhixiao Wang; Xiaoyun Liu; Tao Yang
Journal:  Endocrine       Date:  2020-03-20       Impact factor: 3.633

9.  Graves' Disease Patients with Persistent Hyperthyroidism and Diffuse Lymphoplasmacytic Infiltration in the Thyroid Show No Histopathological Compatibility with IgG4-Related Disease.

Authors:  Eijun Nishihara; Mitsuyoshi Hirokawa; Mitsuru Ito; Shuji Fukata; Hirotoshi Nakamura; Nobuyuki Amino; Akira Miyauchi
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

10.  The Long Noncoding RNA IFNG-AS1 Promotes T Helper Type 1 Cells Response in Patients with Hashimoto's Thyroiditis.

Authors:  Huiyong Peng; Yingzhao Liu; Jie Tian; Jie Ma; Xinyi Tang; Ke Rui; Xinyu Tian; Chaoming Mao; Liwei Lu; Huaxi Xu; Pengcheng Jiang; Shengjun Wang
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.